Letter to the Editor on: The RV144 vaccine regimen was not associated with enhancement of infection

Sandhya VasanU.S. Army Component of The Armed Forces Research Institute of Medical Sciences; U.S. Military HIV Research Program; USAMC-AFRIMS; Bangkok, Thailand

Supachai Rerks-NgarmDepartment of Disease Control; Thai Ministry of Public Health; Nonthaburi, Thailand

Peter GilbertStatistical Center for HIV/AIDS Research and Prevention; Fred Hutchinson Cancer Research Center; Seattle, WAUSA

Barton HaynesHuman Vaccine Institute and the Departments of Medicine and Immunology; Duke University School of Medicine; Durham, NCUSA

Sorachai NitayapanRoyal Thai Army Component of the Armed Forces Research Institute of Medical Sciences; Bangkok, Thailand

Punnee PitisuttihumFaculty of Tropical Medicine; Mahidol University; Bangkok, Thailand

Jaranit KaewkungwalFaculty of Tropical Medicine; Mahidol University; Bangkok, Thailand

Jean-Louis ExclerU.S. Military Research Program; Vaccine Clinical Development; Bethesda, MDUSA

Merlin RobbU.S. Military Research Program; Vaccine Clinical Development; Bethesda, MDUSA

Nelson MichaelU.S. Military Research Program; Vaccine Clinical Development; Bethesda, MDUSA

Jerome KimU.S. Military Research Program; Vaccine Clinical Development; Bethesda, MDUSA

Robert O’ConnellU.S. Army Component of The Armed Forces Research Institute of Medical Sciences; U.S. Military HIV Research Program; USAMC-AFRIMS; Bangkok, ThailandCorrespondence[email protected]

show all

References

Shmelkov E, Nadas A, Cardozo T. Could vaccination with AIDSVAX immunogens have resulted in antibody-dependent enhancement of HIV infection in human subjects? Human vaccines & immunotherapeutics 2014:1–4.
Google Scholar
Haynes BF, Gilbert PB, McElrath MJ, Zolla-Pazner S, Tomaras GD, Alam SM, Evans DT, Montefiori DC, Karnasuta C, Sutthent R, et al. Immune-correlates analysis of an HIV-1 vaccine efficacy trial. N Engl J Med 2012;366:1275–86; PMID:22475592; http://dx.doi.org/10.1056/NEJMoa1113425.
PubMed Web of Science ®Google Scholar
Thongcharoen P, Suriyanon V, Paris RM, Khamboonruang C, de Souza MS, Ratto-Kim S, Karnasuta C, Polonis VR, Baglyos L, Habib RE, et al. A phase 1/2 comparative vaccine trial of the safety and immunogenicity of a CRF01_AE (subtype E) candidate vaccine: ALVAC-HIV (vCP1521) prime with oligomeric gp160 (92TH023/LAI-DID) or bivalent gp120 (CM235/SF2) boost. J Acquir Immune Defic Syndr 2007;46:48–55; PMID:17909315; http://dx.doi.org/10.1097/QAI.0b013e3181576795.
PubMedGoogle Scholar
Pitisuttithum P, Gilbert P, Gurwith M, Heyward W, Martin M, van Griensven F, Hu D, Tappero JW, Choopanya K; Bangkok Vaccine Evaluation Group. Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand. J Infect Dis 2006;194:1661–71; PMID:17109337; http://dx.doi.org/10.1086/508748.
PubMed Web of Science ®Google Scholar
Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, Kaewkungwal J, Chiu J, Paris R, Premsri N, Namwat C, de Souza M, Adams E, et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med 2009;361:2209–20; PMID:19843557; http://dx.doi.org/10.1056/NEJMoa0908492.
PubMed Web of Science ®Google Scholar
Robb ML, Rerks-Ngarm S, Nitayaphan S, Pitisuttithum P, Kaewkungwal J, Kunasol P, Khamboonruang C, Thongcharoen P, Morgan P,Benenson M, et al. Risk behaviour and time as covariates for efficacy of the HIV vaccine regimen ALVAC-HIV (vCP1521) and AIDSVAX B/E: A post-hoc analysis of the Thai phase 3 efficacy trial RV 144. Lancet Infect Dis 2012;12:531–7; PMID:22652344; http://dx.doi.org/10.1016/S1473–3099(12)70088–9.
PubMed Web of Science ®Google Scholar
Tomaras GD, Ferrari G, Shen X, Alam SM, Liao HX, Pollara J, Bonsignori M, Moody MA, Fong Y, Chen X, et al. Vaccine-induced plasma IgA specific for the C1 region of the HIV-1 envelope blocks binding and effector function of IgG. Proc Natl Acad Sci U S A 2013;110:9019–24; PMID:23661056; http://dx.doi.org/10.1073/pnas.1301456110.
PubMed Web of Science ®Google Scholar

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Letter to the Editor on: The RV144 vaccine regimen was not associated with enhancement of infection

References

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Letter to the Editor on: The RV144 vaccine regimen was not associated with enhancement of infection

References

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date